EULAR Annual Meeting in London, UK | 2026 | News | Updates | iPharmaCenter
- Badari Andukuri
- 1 day ago
- 2 min read
Bimzelx Leads in Head-to-Head PsA Trial, Surpassing Skyrizi at Week 16
Bimzelx (bimekizumab) has demonstrated greater efficacy than Skyrizi (risankizumab) in treating psoriatic arthritis, based on Week 16 results from the BE BOLD trial.
What is the efficacy comparison of Bimzelx vs Skyrizi in psoriatic arthritis?
At Week 16, 49.1% of patients treated with bimekizumab achieved the ACR50 primary endpoint, compared with 38.4% of those receiving risankizumab, confirming statistically significant superiority in joint response outcomes.
This marks the first instance where an approved biologic has shown clear superiority in ACR50 results in a head-to-head psoriatic arthritis study.
Secondary outcomes generally favored bimekizumab, although not all reached statistical significance.
Minimal disease activity (MDA) at Week 16 was achieved by 43.0% of patients on bimekizumab versus 39.9% on risankizumab. Because the statistical testing hierarchy stopped at this endpoint, subsequent secondary outcomes were evaluated descriptively.
Early response was also more pronounced with bimekizumab. By Week 4, 19.9% of patients achieved ACR50 compared with 7.2% in the risankizumab group, indicating faster onset of joint improvement.
In terms of skin outcomes, complete clearance (PASI100) at Week 16 was observed in 53.4% of patients treated with bimekizumab and 46.6% of those receiving risankizumab.
Additionally, combined ACR50 and PASI100 responses were higher with bimekizumab (33.5% vs 24.4%).
Also read: Baxfendy (baxdrostat) Approved in the US as First Aldosterone Synthase Inhibitor for Uncontrolled Hypertension
Further exploratory measures also supported bimekizumab’s efficacy. Low disease activity based on DAPSA (score ≤14) was achieved by 65.3% of patients in the bimekizumab group compared with 54.7% in the risankizumab group.
The safety profiles of both treatments were broadly similar. Treatment-emergent adverse events occurred in 57.0% of patients receiving bimekizumab and 52.0% of those on risankizumab.
The BE BOLD study is a randomized, double-blind, active-controlled trial involving 553 adults with active psoriatic arthritis. Participants included both biologic-naïve patients and those who had previously received one TNF inhibitor with inadequate response or intolerance.
Comments